These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Minimal antiproliferative effect of recombinant müllerian inhibiting substance on gynecological tumor cell lines and tumor explants. Wallen JW; Cate RL; Kiefer DM; Riemen MW; Martinez D; Hoffman RM; Donahoe PK; Von Hoff DD; Pepinsky B; Oliff A Cancer Res; 1989 Apr; 49(8):2005-11. PubMed ID: 2702642 [TBL] [Abstract][Full Text] [Related]
8. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo. Pieretti-Vanmarcke R; Donahoe PK; Szotek P; Manganaro T; Lorenzen MK; Lorenzen J; Connolly DC; Halpern EF; MacLaughlin DT Clin Cancer Res; 2006 Mar; 12(5):1593-8. PubMed ID: 16533786 [TBL] [Abstract][Full Text] [Related]
9. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763 [TBL] [Abstract][Full Text] [Related]
10. The müllerian inhibitor and mammalian sexual development. Behringer RR Philos Trans R Soc Lond B Biol Sci; 1995 Nov; 350(1333):285-8; discussion 289. PubMed ID: 8570693 [TBL] [Abstract][Full Text] [Related]